On Jul. 30, 2020, Seqirus announced it had begun shipping its portfolio of seasonal influenza vaccines to customers in the U.S. for the 2020/21 influenza season. Seqirus is one of the world’s largest influenza vaccine companies and is well-positioned to supply up to 60 million doses for the U.S. market this year, depending on demand.

Seqirus has a broad portfolio of differentiated products for individuals six months of age to adults 65 years and older, presented in pre-filled syringes as well as multi-dose vials. In 2020, Seqirus provided FLUAD® (Influenza Vaccine, Adjuvanted), the first-and-only adjuvanted seasonal influenza vaccine approved for adults 65 and older, in addition to FLUAD® Quadrivalent (Influenza Vaccine, Adjuvanted). FLUAD® Quadrivalent contains an additional B strain to help prevent disease caused by all 4 influenza strains represented in the vaccine.